Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

• Published in: Current reviews in clinical and experimental pharmacology Vol. 17; no. 1; p. 18
• Main Authors: Shuster, Diana L, Pastino, Gina, Cerneus, Dirk
• Format: Journal Article
• Language: English
• Published: Netherlands 2022
• Subjects: Adult; Cannabidiol - pharmacology; Cannabis - adverse effects; Clinical Trials, Phase I as Topic; Drug Interactions; Humans; United States; United States; cannabidiol; clinical pharmacology; Cannabis; delta-9-tetrahydrocannabinol; drug-drug interactions; marijuana
• DOI: 10.2174/2772432816666210813123716

Cannabis has become legal in much of the United States similar to many other countries, for either recreational or medical use. The use of cannabis products is rapidly increasing while the body of knowledge of its myriad of effects still lags. and clinical data show that cannabis' main constituents, delta-9-tetrahydrocannabinol and cannabidiol, can affect pharmacokinetics (PK), safety, and pharmacodynamics (PD) of other drugs. Within the context of clinical drug development, the widespread and frequent use of cannabis products has essentially created another special population: the cannabis user. We propose that all clinical drug development programs include a Phase 1 study to assess the drug-drug interaction potential of cannabis as a precipitant on the PK, safety, and if applicable, the PD of all new molecular entities (NMEs) in a combination of healthy adult subjects as well as frequent and infrequent cannabis users. This data should be required to inform drug labeling and aid health care providers in treating any patient, as cannabis has quickly become another common concomitant medication and cannabis users, a new special population.